Market Overview

UPDATE: Jefferies Raises PT on Infinity Pharmaceuticals on IPI-145 Sales Potential

Related INFI
JPM Securities Picks Through Biotech News For Winners
UPDATE: Infinity Pharmaceuticals Posts Q4 Loss

In a report published Wednesday, Jefferies reiterated its Hold rating on Infinity Pharmaceuticals (NASDAQ: INFI), and raised its price target from $21.00 to $41.00.

Jefferies noted, “Wider 4Q12 loss of ~$47M (vs. our loss estimate of ~$29M); cash of $327M at YE12 sufficient into ~2015. With expanding cohorts in Ph1/2a, timing for Ph3 start is likely in ~2014. INFI's rising valuation implies IPI-145 sales potential at >~$3B; however, given evolving competitive field with several promising products well ahead of IPI-145, speedy, comprehensive development strategy is key to realizing its commercial potential.”

Infinity Pharmaceuticals closed on Tuesday at $45.14.

Latest Ratings for INFI

Jan 2015Morgan StanleyDowngradesOverweightEqualweight
Dec 2014Credit SuisseUpgradesNeutralOutperform
Nov 2014NomuraMaintainsNeutral

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→